MASS · 908 Devices
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $12.87
Note written ·
Price against the kill line
24.3% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $12.87, on record since 11 November 2026. The shares are down 4.4% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $12.87, near the October peak, would show the shares recovering the post-results loss and leading the S&P 500. Fourth-quarter revenue that lifts 2026 above the $70.0 million top of the outlook would also prove the call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 10 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 18.9
- Revenue, change on a year (%)
- +35.3
- Gross margin (%)
- 52.9
- Operating margin (%)
- −28.9
- Net cash, cash less debt ($M)
- 99.1
- Enterprise value to sales (×)
- 4.6
All filed numbers
What 908 Devices reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 18.9 | +35.3 | 52.9 | −28.9 |
| first filed | 16.1 | +23.3 | 51.9 | −79.7 |
| first filed | 13.4 | +13.6 | 51.4 | −96.3 |
| first filed | 17.4 | +21.2 | 52.7 | 17.8 |
| first filed | 14.0 | −3.5 | 52.5 | −116.6 |
| first filed | 13.0 | +13.7 | 48.9 | −116.3 |
| Pre-tax income ($M) | −4.6 |
| Net income ($M) four quarters: −24.3 | −4.6 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +13.8 |
| Operating cash flow ($M) | 2.9 |
| Capital spending ($M) | Not available |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 99.1 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 99.1 |
| Deferred revenue ($M) +25.0% on a year | 22.9 |
| Backlog, orders not yet delivered ($M) +25.0% on a year | 22.9 |
| Receivables ($M) | 17.2 |
| Inventory ($M) | 14.7 |
| Shareholders' equity ($M) | 150 |
| Market value ($M) | 405 |
| Enterprise value, market value plus net debt ($M) no debt reported | 306 |
| Enterprise value to sales (×) no debt reported | 4.6 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 2.7 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 6.5% of shares outstanding sold short, 7.1 days of average trading to cover, −0.7% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $2.5M |
| 12 monthsfrom | $0 | $10.3M |
The thesis
908 Devices' shares are more likely to lag the S&P 500 over the next three months, even after a third-quarter beat. The market sold the report, and management says the 2026 outlook implies fourth-quarter growth of about 20% at its midpoint. The 2027 outlook, which management plans to give early in 2027, shows whether NIRLab and AvCAD can bring back faster growth.
The company reported third-quarter revenue of $18.95 million on 10 November 2026, up 35% from $14.0 million a year earlier. Analysts had expected $18.3 million. The adjusted loss of 11 cents per share beat the 17-cent estimate. The company raised the floor of its 2026 revenue outlook to $68.5 million and kept the ceiling at $70.0 million.
The shares closed at $11.51 on 9 November 2026 and at $9.98 on 10 November 2026, the day of the report. By the 11 November 2026 close of $10.06, the three-month change was −0.5%. The price has given back the pre-report rise and reflects a business growing at 20–35% a year with losses still on the books.
The rating is Low because one order and two customers drove much of the quarter. Management said on the 10 November 2026 call that about two-thirds of the $6 million ProtectIR order shipped in the third quarter. It also said two customers accounted for about 41% of quarterly revenue. A director kept selling shares under a pre-arranged plan into the report.
Bullish and bearish views on 908 Devices Inc.
The bull case on 908 Devices Inc. (MASS), in brief: growth sped up to a record quarter. The bear case: fourth-quarter growth slows.
Bull case
- Growth sped up to a record quarter. Third-quarter revenue rose 35%, up from 23% in the second quarter, according to the company's 10 November 2026 and 11 August 2026 releases. Product revenue was $15.8 million, against $10.8 million a year earlier.
- The reported loss narrowed sharply. The third-quarter net loss from continuing operations was $4.6 million, against $14.9 million a year earlier. That includes an $11.0 million noncash swing in the fair value of contingent consideration (10 November 2026 release). Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), a non-GAAP measure, was a $1.7 million loss. Management expects the 2026 adjusted EBITDA loss in the mid-single-digit millions, about one-third smaller than in 2025.
- Unit placements hit a record. The company placed 308 devices in the quarter, and its installed base reached 4,409, up 26% year over year (10 November 2026 release). About 100 NIRLab devices brought in $1.2 million of revenue. The chief financial officer said that if the fourth quarter repeats, NIRLab could reach nearly $3 million for 2026 and more than $5 million in 2027.
- AvCAD moved a step forward. On the 10 November 2026 call, management said MX908 devices had been delivered to the US Army's chemical, biological, radiological and nuclear (CBRN) defense office for testing. It said a commercial off-the-shelf purchasing route could bring orders in 2027. AvCAD remains outside the 2026 outlook.
- The balance sheet funds the losses. The company held $99.1 million in cash, cash equivalents and marketable securities and no debt on 30 September 2026. Stifel kept its Buy rating and raised its price target to $14 on 11 November 2026.
Bear case
- Fourth-quarter growth slows. Management said on 10 November 2026 that the midpoint of the outlook implies about 20% fourth-quarter growth. Reaching the top of the range needs about 24%, and that depends on a handful of larger enterprise deals and on when funding arrives.
- Revenue is concentrated. Two customers made up about 41% of third-quarter revenue, and about two-thirds of the $6 million ProtectIR order shipped in that quarter, according to the 10 November 2026 call. The 10-Q attributes the growth in FTIR (infrared spectroscopy) products mainly to shipments to an Asia-Pacific corrections agency.
- Product mix is pressuring margins. Adjusted gross margin was 58% in the third quarter, down 40 basis points because of lower-margin international sales. The margin under generally accepted accounting principles (GAAP) was 53% (10 November 2026 release and call). International customers provided 40% of quarterly revenue.
- US state and local sales fell back. US state and local customers provided about 25% of third-quarter revenue, against more than 40% for the year to date. Management linked the drop to strong MX908 placements in the first half and the timing of ProtectIR shipments (10 November 2026 call).
- Insiders keep selling. Director Christopher D. Brown sold 30,000 shares at $10.95 on 4 November 2026. He had also sold 30,000 at $11.89 on 7 October 2026 and 30,000 at $10.58 on 2 September 2026, all under Rule 10b5-1 pre-arranged plans (SEC Form 4 filings). The chief financial officer sold 5,000 shares at $13.03 on 6 October 2026. AWM Investment Company, a 10% owner, sold 18,000 shares at $11.52 on 29 September 2026.
Price setup
The shares closed at $10.06 on 11 November 2026, 24.6% below the 52-week intraday high of $13.35 set on 6 October 2026. The 52-week closing low is $5.09, on 2 January 2026. The three-month change of −0.5% runs from the $10.11 close on 13 August 2026.
The last close sits below the 50-day moving average of $11.18 and above the 200-day moving average of $8.53, both as of 11 November 2026. The $9.98 close on 10 November 2026 is the low after the results. A sustained close back above the 50-day average would show the post-results selling reversing. A close under $9.98 would extend the post-results decline toward the 200-day average.
Catalysts ahead
- ~31 December 2026 (est.): Early-access shipments of the next-generation MX908, targeted by management for year-end 2026. These shipments are one of the three growth drivers management named for 2027. A delay would weaken the 2027 case.
- ~5 March 2027 (est.): Fourth-quarter 2026 results and the first 2027 revenue outlook. Shows whether 2026 ends above or below the $68.5–70.0 million range. It also shows whether the 2027 outlook includes NIRLab growth and any AvCAD orders.
What would change the view
A daily close above $12.87, near the October peak, would show the shares recovering the post-results loss and leading the S&P 500. Fourth-quarter revenue that lifts 2026 above the $70.0 million top of the outlook would also prove the call wrong.
What it trades with
908 Devices trades on its own order flow rather than with a group of peers. Its revenue depends on government purchasing: international agencies (40% of third-quarter revenue), US state and local buyers, and the US Army through the AvCAD program. Defense and public-safety budgets are the closest sector influence.
The company is a small, loss-making firm with a large cash balance, so its shares tend to move with small-cap indexes and with appetite for risk. Large single orders, such as the $6 million ProtectIR contract, can swing a quarter's growth rate.
The evidence, claim by claim (8)
- Third-quarter 2026 revenue was $18.95 million, up 35% from $14.0 million. Product revenue was $15.8 million and recurring revenue $5.1 million. 908 Devices third-quarter 2026 results release (8-K) · as of
- The third-quarter net loss from continuing operations was $4.6 million, against $14.9 million a year earlier. The adjusted EBITDA loss was $1.7 million, against $1.8 million. 908 Devices third-quarter 2026 results release (8-K) · as of
- The 2026 revenue outlook was raised to $68.5–70.0 million from $68.0–70.0 million. Nine-month revenue was $48.4 million, against $38.8 million a year earlier. 908 Devices third-quarter 2026 results release (8-K) · as of
- The company held cash, cash equivalents and marketable securities of $99.1 million and no debt. 908 Devices third-quarter 2026 10-Q · as of
- About two-thirds of the $6 million ProtectIR order shipped in the third quarter. Two customers accounted for about 41% of quarterly revenue. 908 Devices third-quarter 2026 earnings call · as of
- MX908 devices were delivered to the US Army's CBRN defense office for testing. Management said a commercial off-the-shelf route could bring AvCAD orders in 2027. 908 Devices third-quarter 2026 earnings call · as of
- Director Christopher D. Brown sold 30,000 shares at $10.95 under a Rule 10b5-1 plan. SEC Form 4 filed 6 November 2026 · as of
- Stifel kept its Buy rating on 908 Devices and raised its price target to $14. Stifel analyst action reported 11 November 2026 · as of
Sources
- 908 Devices Inc. - Form 8-K - FY2026 · sec.gov
- Earnings call transcript: 908 Devices beats Q3 2026 estimates, shares fall premarket · ng.investing.com ·
- 908 Devices Inc. - Form 10-Q - FY2026 · sec.gov
Related · shared themes
AVEX
AEVEX
AEVEX's core drone and maritime business is outgrowing its fading Ukraine work, making the shares modestly likely to beat the S&P 500 over…
BA
Boeing
Boeing's shares look more likely to lag the S&P 500 because 737 MAX deliveries fell to 32 in October 2026 and its airplane unit is cutting…
ENVX
Enovix
Enovix shares are more likely to lag the S&P 500 over three months after the company dropped smartphone field testing and guided…
CACI
CACI International
CACI International is more likely to beat the S&P 500 over three months: fiscal 2027 guidance was raised on 21 October 2026 and funded…